TE 8105
Alternative Names: TE-8105Latest Information Update: 11 Sep 2024
At a glance
- Originator Immunwork
- Class Antihypercalcaemics; Drug conjugates; Fatty acids; Glucagon-like peptides; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 05 Sep 2024 Phase-I clinical trials in Non-alcoholic steatohepatitis (SC) (Immunwork pipeline, September 2024)
- 05 Sep 2024 Phase-I clinical trials in Type 2 diabetes mellitus (SC) (Immunwork pipeline, September 2024)
- 07 Jun 2024 Phase-I clinical trials in Obesity in Australia (SC) (NCT06471530)